Session Schedule

Here are the content details for this event's available sessions.
All times are Eastern Time Printable Schedule || Times, presenters and sessions are subject to change.

Day 1 || Day 2
Time
Title
Speaker
 

     All Sessions   |   Room 1   |   Room 2
  • Day 1

  • 5/16/2015 11:00 AM
    -to-
    12:05 PM
    Keratoconus and Keratoectasia – Contemporary Concepts: Disease Description and Diagnosis (44999-AS)
       
    Keratoconus diagnosis and its management is complex. Appropriate diagnosis, assessment, and treatment can allow a patient to achieve excellent vision performance and function normally in life. Inappropriate care can result in poor vision function, chronic discomfort, physiological compromise and perhaps a faster road towards invasive surgical intervention (which may not have been necessary). This course will review the most contemporary concepts in the diagnosis of keratoconus and other corneal ectasias. We will review methods and technologies that allow for early diagnosis of ectasia. Utilization of both basic diagnostic techniques and advanced diagnostic technologies will provide the opportunity to incorporate an array of treatment options that range from optical to medical to surgical. Today early diagnosis coupled with new treatment strategies can not only optimize vision but can also prevent progression to advanced disease for patient with kertatoectasia. The presenter will share both experience in managing thousands of patients with ectasia as well as outcomes of the most current state of science in this field.
  • 5/16/2015 11:00 AM
    -to-
    12:00 PM
    Just the Facts: Partnerships, Associate Agreements and Buying/Selling a Practice (44936-PM)
       
    Optometrists know eyes, not contracts. A basic understanding of contract law is an essential part of owning a practice. Just the Facts: Partnerships, Associate Agreements and Buy/Sell Contracts will dive into the specifics of what to look for and what needs to be included in these three kinds of contracts commonly seen in private practices. The talk includes a thorough discussion of the different forms of ownership and the differences, pros and cons of each, the special considerations that go into hiring associate doctors, and what goes into the set of agreements commonly seen in practice buy/sell transactions.
  • 5/16/2015 12:00 PM
    -to-
    1:00 PM
    Fundamental consideration in Digital Age Marketing (45164-PM)
       
    This course aims to cover fundamental business concepts vital to optometry and focused to target information centric consumer. Topics covered include fundamental marketing concepts, website functionality, search engine strategies, use of social media, blogs and video for promotional marketing and search optimization and direct to consumer advertising using direct email marketing and targeted advertising.
  • 5/16/2015 12:05 PM
    -to-
    1:05 PM
    Lifestyle Decisions: What Does the Science Say (44790-GO)
       
    With stress reduction being a major risk factor for ARMD, Dr. Newman presents a 1-hour webinar discussing clinical studies related to reducing stress levels in patients at risk for Age Related Macular Degeneration.

    Dr. Newman breaks down the NIH studies “Stress Reduction Programs in Patients with Elevated Blood Pressure: A Systematic Review and Meta-analysis” authored by Maxwell V. Rainforth, PhD, Robert H. Schneider, MD, Sanford I. Nidich, EdD, Carolyn Gaylord-King, PhD, John W. Salerno, PhD, and James W. Anderson, MD and published in Current Hypertension Reports 2007, 9:520–528, where we learn that many stress reducing programs have shown benefits, relaxation, meditation and biofeedback techniques will be discussed in detail, as well as “A Randomized Controlled Trial of Stress Reduction in African Americans Treated for Hypertension for Over One Year” published in 2005 by the American Journal of Hypertension which determined that psychosocial stress has been implicated in the disproportionately higher rates of hypertension among African Americans. This randomized controlled trial compared the effects of two stress reduction techniques and a health education control program on hypertension during a period of 1 year in African-American men and women.
  • 5/16/2015 1:00 PM
    -to-
    2:00 PM
    Using Body Weight to Monitor the Stability of the Hyperglycemic Patient (44675-SD)
       
    This course introduces the concept of using a single parameterproxy that can signal the stability of a hyperglycemic patient. This creates a potential role for optometry in collaborating with primary care medicine in diabetic self-management and education.
  • 5/16/2015 1:05 PM
    -to-
    2:05 PM
    Genetics and Epigenetics in a Post Darwinian Age (45226-PS)
       
    We discuss the authors’ take on the role of genetic testing in AMD. Lost in the statistical risk controversy is the fact that one’s DNA is not ones destiny. Rather DNA can be changed, for instance, by several biochemical mechanisms established over the last few decades. Identical twins may start off with identical DNA, but as they grow up their DNA expression, and hence risk of AMD changes based upon their environment and individual decision-making.
  • 5/16/2015 2:00 PM
    -to-
    3:00 PM
    Carotid Stenosis: The Manifestations and Clinical Spectrum of Ocular Findings (43525-SD)
       
    This course will discuss the ocular manifestations of carotid artery stenosis. The presentation will use two case examples to demonstrate the ocular findings of carotid artery disease and ocular ischemic syndrome. The course also discusses the various diagnostic tests used as well as the ocular and surgical management of carotid stenosis.
  • 5/16/2015 2:05 PM
    -to-
    3:05 PM
    AREDS 2 and beyond - Lutein / Mesozeaxanthin and Zeaxanthin (45225-PS)
       
    We review how to identify the “high risk AMD patient” , the actual data within the JAMA publications and what it tells us about prevention of catastrophic vision loss in patients who have high risk of developing AMD. Next we explore what to tell the 90 % of patients who don’t have high risk AMD, yet are loosing vision from mild and moderate AMD that effects their night driving and overall visual performance. We explore Level 2 science about mesozeaxanthin and new instrumentation that are enhancing and invigorating the practice of optometry.
  • 5/16/2015 3:00 PM
    -to-
    3:15 PM
    Break
       
     
  • 5/16/2015 3:05 PM
    -to-
    3:20 PM
    Break
       
     
  • 5/16/2015 3:15 PM
    -to-
    4:15 PM
    Blepharitis/MGD and Demodex (45036-AS)
       
    This course will review the latest trends in the diagnosis and management of blepharitis, meibomian gland dysfunction and demodex infestation. The dry eye of the 90's has evolved from aqueous deficiency to what we know today. Research is now leading us to the lid margin as the central cause. The role of eyelid disease in ocular surface disease will be the theme of this discussion.
  • 5/16/2015 4:15 PM
    -to-
    5:15 PM
    Medical Coding and Billing Implementation (45198-PM)
       
    The purpose of this course is the give a roadmap for the implementation of medical billing protocols. It’s designed for those new to medical billing to give a step-by-step guide for credentialing and office procedures related to patient handling. It will give an overview of the necessary steps to becoming a medical insurance provider as well as patient intake paperwork and phone scripts and office worker training.
  • 5/16/2015 4:20 PM
    -to-
    5:20 PM
    Treating the Eye with Autologous and Allogeneic Serum Administration (44791-AS)
       
    This course details the use of blood serum in the treatment of anterior ocular surface disease. The details and logistics of prescribing and acquiring autologous and allogenic blood serum is detailed. Modern techniques for fortifying serum is also covered.
  • 5/16/2015 5:15 PM
    -to-
    6:15 PM
    Billing and Coding the Medical Eye Examination (45205-PM )
       
    You will learn how to properly report a medical eye examination based on Current Procedural Terminology (CPT) definitions. Topics include information on how to determine medical necessity and how to improve your medical decision making.
  • 5/16/2015 5:20 PM
    -to-
    6:20 PM
    Dailies News: The Revolution in One Day Lenses (44794-CL)
       
    Single use lenses provide unique benefits to the contact lens wearer. Eye care providers are embracing this technology at an ever increasing rate. Factors contributing to greater acceptance and usage within the ophthalmic community include reduced incidence of adverse events, a continuing influx of new designs along with expansion of parameters in existing designs, and improved patient education. This course will review the clinical indications for daily disposable fitting, review new lens designs, and provide a rationale for lens selection.
  • 5/16/2015 6:20 PM
    -to-
    7:20 PM
    Exploring the Globe with Technologies That Image a Mile Wide and a Mile Deep (45149-SD)
       
    Novel technologies lead to both early and new disease identification. EDI OCT and Multi-Spectral Imaging reveal disorders at various depths otherwise invisible. Panoramic auto-fluorescence reveals RPE defects not observable with BIO. This course highlights these and other technologies and the disorders that are uncovered, some for the first time.
  • Day 2

  • 5/17/2015 11:00 AM
    -to-
    12:00 PM
    Keratoconus and Keratoectasia – Contact Lens, Medical and Surgical Treatments (45007-AS)
       
    Keratoconus diagnosis and its management is complex. Appropriate diagnosis, assessment, and treatment can allow a patient to achieve excellent vision performance and function normally in life. Inappropriate care can result in poor vision function, chronic discomfort, physiological compromise and perhaps a faster road towards invasive surgical intervention (which may not have been necessary). This course will review the most contemporary concepts in the treatment of patients with keratoconus and other corneal ectasias. Today early diagnosis coupled with new treatment strategies can not only optimize vision but can also prevent progression to advanced disease for patient with kertatoectasia. The presenter will share both experience in managing thousands of patients with ectasia as well as outcomes of the most current state of science in this field.
  • 5/17/2015 11:00 AM
    -to-
    12:00 PM
    Building the Medical Model Practice (45150-GO)
       
    Learn the strategies and secrets of developing the medical aspect of your practice. Discover the tools, the philosophy and the strategies of developing the medical model.
  • 5/17/2015 12:00 PM
    -to-
    1:00 PM
    A New View of MGD: The Leading Cause of Dry Eye Can Be Treated! (44796-AS)
       
    Challenges in the treatment and management of evaporative dry eye include the reliability of diagnostic methods and patient compliance with therapeutic regimens. Ongoing scientific research on meibomian gland dysfunction has led to recent advances in diagnostic devices and innovative treatment modalities aimed at improving clinical outcomes.
  • 5/17/2015 12:00 PM
    -to-
    1:00 PM
    ICD-10 Implementation – HIPAA - How to Avoid and Survive Audits (44830-PM)
       
    There are more significant and difficult changes impacting Eyecare practices this year than in previous years. ICD-10 will be implemented this year. ICD-10 is not a logical extension of ICD-9 and is confusing to many practices. In addition, many articles and seminars have incorrect information on ICD-10. Meaningful Use Incentive Payments - Numerous practices have received incentive payments for from CMS. CMS has hired a firm to conduct audits on practices who have received incentive payments. More practices fail an audit than pass. Many recent changes to HIPAA. Most practices are using out of date HIPAA forms. Insurance Audits have significantly increased in the past couple or years.
  • 5/17/2015 1:00 PM
    -to-
    2:00 PM
    Advances in Anterior Segment Therapy (45246-AS)
       
    This course will review the latest literature that impacts diagnosis, treatment and management of patients in the primary care Optometry practice.
  • 5/17/2015 1:00 PM
    -to-
    3:00 PM
    Mastering OCT Interpretation (45178-PD)
       
    OCT has become an integral tool for many eye care practitioners in the diagnosis and monitoring of retinal disease. This course will teach how to interpret OCT. Both normal anatomy and pathologic states will be demonstrated. Finally, numerous mystery cases will be presented to allow the audience to utilize the skills acquired through the course.
  • 5/17/2015 2:00 PM
    -to-
    3:00 PM
    Advances in Glaucoma Therapy (45245-GL)
       
    This course will review the latest technologies for both the diagnosis and treatment of glaucoma. Special emphasis will be placed on the implementation of these systems into primary care practice.
  • 5/17/2015 3:00 PM
    -to-
    4:00 PM
    Imaging Update – OCT and Fundus Imaging (44977-PS)
       
    Although fundus observation with ophthalmoscopy BIO remain the standard of care, myriad imaging devices continue to reveal that many disorders are invisible to BIO in early stages. OCT allows us to assess each retinal layer including, for example, the photoreceptors, which are never visible with BIO. Advances in OCT allow views of 12x9 mm of fundus as well as revealing the choroid as never before. Multi-spectral imaging MSI using 10 or more LEDs allow detection of RPE and choroidal lesions often invisible to even OCT. Ultra-widefield UWF devices allows over 80 of the fundus to be viewed in 1 image. Auto-fluorescence AF permits imaging thqt goes beyond structure and reveals function RPE involvement is often invisible to all other devices, save for AF. UWF fluorescein angiography permits vascular leakage to be documented beyond the equator. Although not FDA approved, devices that document B-amyloid plaques the bio-marker for Alzheimers disease- AD in the retina will soon be available.
  • 5/17/2015 3:00 PM
    -to-
    4:00 PM
    AMD-How to Open a Diagnosis and Prevention Center in Your Office (45093-PS)
       
    An overview of basic equipment and techniques to help the practitioner take an active role in the diagnosis, treatment and prevention of AMD
  • 5/17/2015 4:00 PM
    -to-
    4:15 PM
    Break
       
     
  • 5/17/2015 4:00 PM
    -to-
    4:15 PM
    Break
       
     
  • 5/17/2015 4:15 PM
    -to-
    5:20 PM
    Early Detection of Myriad Retinal and Choroidal Disorders with Fundus Auto Fluorescence (44978-PS)
       
    Fundus AutoFluorescence is a novel, non-invasive imaging method that yields abnormalities that are often invisible to ophthalmoscopy and fundus photography. It allows mapping of lipofuscin distribution in the retina which are crucial findings in retinopathies.
  • 5/17/2015 4:15 PM
    -to-
    6:15 PM
    Advanced Diagnosis and Management of Ocular Surface Disease and Tear Dysfunction (45197-AS)
       
    Our understanding of the ocular surface has evolved dramatically over the past few years. We increasingly recognize the complexity and interaction of ocular surface elements and tear structure. Combining an evidence-based approach with extensive use of video animation, this course integrates novel concepts into a unified perspective of the ocular surface environment with direct clinical application.
  • 5/17/2015 5:20 PM
    -to-
    6:20 PM
    Dynamic Developments in AMD Dx and Tx The Dawn of Pharmaco-Genetics (44981-PS )
       
    AMD is the most common etiology of vision loss in the US. AREDS 12 confirm that anti-oxidants and zinc can reduce the risk of progressing from Category 3 AMD to more serious vision loss by about 25. However, based upon a landmark study published in Aug 2013 in the journal Ophthalmology, the presence or absence of high risk alleles in CFH and ARMS2 genes determines the most effective nutraceuticals for each patient.
  • 5/17/2015 6:15 PM
    -to-
    7:15 PM
    Current Status on the Development and Treatment of Myopia (45259-GO)
       
    This is a review of the current literature describing the effect of atropine, bifocals, andor contact lenses on slowing the progression of myopia. Cumulative data from a number of studies have demonstrated atropine instilled once a day in myopic eyes resulted in a 90 average reduction of myopia progression, as compared to untreated eyes, i.e., from 0.50 Dyear to 0.05 Dyear. Pirenzepine, a muscarinic pharmacological agent, has a minimal effect on pupil size and accommodation, and it has been shown to slow myopia by 44. Bifocals and progressive lenses, which have been used for years to slow the progression of myopia, have recently been shown to produce, on average, only small, clinically insignificant treatment effects. However, their effectiveness is increased in children who are esophoric and have a large lag of accommodation, reducing myopia progression to between 0.25 and 0.40 Dyear. Traditional correcting soft and gas permeable contact lenses, as well as novel spectacle lens designs, have not been shown to be effective in reducing myopic progression. Under-correction of the refractive error has been shown not only to be ineffective in slowing myopia, but has also been associated with an increased rate of myopia progression. Orthokeratology, using reverse geometry designed lenses, has been shown to be moderately effective in decreasing the progression of myopia by between 30 to 50 in a number of short-term, well-controlled studies, reducing myopia progression to between -0.35 and -0.25 Dyear. Recently, there have been pilot studies using novel peripherally correcting soft contact lenses to slow the progression of myopia. Two of those lens designs have been shown to be moderately effective in slowing the progression of myopia, both of which had a 30 efficacy, reducing myopia progression to 0.35 Dyear. In summary, myopia control is entering a new era with the use of contact lenses and pharmaceutical agents to effectively slow its progression with minimal side effects.
Panel Bottom